Study Phase 2

A Phase 2 Multicenter, Randomized, Double-blind, Placebo-Controlled, Trial to Evaluate Toreforant (JNJ-38518168) for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis

Trial Information

Generic NameToreforantProduct NameN/ATherapeutic AreaRespiratory SystemProduct ClassAntihistamines for Systemic UsePharmacological SubgroupAntihistamines for Systemic UseChemical SubgroupOther Antihistamines for Systemic UseCondition StudiedPsoriasis
Sponsor Protocol Number38518168PSO2001Enrollment62Data PartnerJohnson & Johnson% Female55.0%Mean/Median Age (Years)39.0% White57.0%

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.